Celsion craters 65% on dim hopes for ThermoDox in liver cancer

Celsion (NASDAQ:CLSN) plummets 65% premarket on robust volume in reaction to its announcement that the independent Data Monitoring Committee (DMC) has recommended the termination of the Phase 3 OPTIMA study evaluating ThermoDox, combined with radiofrequency ablation (RFA), in patients with hepatocellular carcinoma or primary liver can